Bill
SB 5263
Establishes a state framework to study and regulate supervised psilocybin services for adults 21+, via advisory boards, a pilot, and phased rulemaking, with equity guardrails.
Status: Enacted as Second Substitute (2023 Regular Session); Governor partially vetoed 5/9/2023. Chapter 364, 2023 Laws. Effective date: July 23, 2023.
Purpose / intent
- Establish a state-level framework to plan for and regulate legal, supervised access to psilocybin services for adults (21+).
- Prioritize public health and safety, prevent diversion and underage access, and promote equitable access (including a “social opportunity” element to remedy past disparate enforcement).
Key provisions and changes
- New statutory chapter (“Washington psilocybin services act”) with broad goals: program development, safety, regulation of products/services, diversion prevention, and equity.
- Definitions: clarifies terms such as “psilocybin,” “psilocybin products” (includes psilocybin-producing fungi and mixtures with detectable psilocybin), “manufacture,” “client,” “licensee,” and “permitted location.”
- Advisory bodies created:
- Washington Psilocybin Advisory Board (within Department of Health, DOH) to advise DOH, the Liquor & Cannabis Board (LCB), and the Department of Agriculture (WSDA). Composition: appointed stakeholder and expert members (public health, health equity, palliative care, substance use disorder policy, indigenous use, veterans, clinicians, mycology/ethnobotany/psychopharmacology/harm reduction researchers, LCB designee, Attorney General/designee, etc.). Members serve 4‑year terms (at governor’s pleasure). Meeting frequency: minimum 5 times/year until 7/1/2024, then at least quarterly. Board may adopt rules needed for its operation.
- Interagency Psilocybin Work Group (DOH, LCB, WSDA) to provide regular updates to the Advisory Board on building a comprehensive regulatory framework (including product cleanliness/pesticide controls; review of indigenous practices and clinical findings; ensuring social opportunity program inclusion).
- Psilocybin Task Force (established by Health Care Authority, HCA) to review clinical evidence and regulatory options and report to Governor & Legislature; the bill directed a final report by Dec. 1, 2023 (per the 2023 text).
- Department of Health powers: authority to examine, publish, and distribute medical/psychological/scientific information about psilocybin safety and efficacy; rulemaking authority to implement the regulatory framework; and other specified regulatory powers tied to licensing, safety, and oversight.
- Pilot research program: establishes a Psilocybin Therapy Services Pilot Program at the University of Washington Department of Psychiatry & Behavioral Sciences (for program development/clinical work).
- Program scope and limits:
- Intended to permit licensed manufacture of psilocybin products and licensed provision of psilocybin services to adults after a program development period (statutory language contemplates a multi‑year development and rulemaking phase prior to full implementation).
- Permitted locations can include approved non-service‑center sites (examples in text: veterans organizations, houses of worship, private residences, outdoor spaces), with exclusions (vehicles and public spaces).
- Explicitly does not require public or private insurers to reimburse psilocybin services and does not override federal contract/grant conditions; does not obstruct federal law enforcement.
- Equity element: requires consideration of a social opportunity (equity) program within any licensing structure to address harms from prior targeted enforcement.
- Other elements (in statutory text): licensing and oversight concepts, tracking/testing expectations, and references to coordination with systems used in cannabis regulation (Cannabis Central Reporting System experience).
Who/what is affected
- Adults 21+ seeking supervised psilocybin services (future regulatory rollout); psilocybin service centers, facilitators, and manufacturers (once licensing is implemented); DOH, LCB, WSDA, HCA and other state agencies for rulemaking and oversight; the University of Washington (pilot program); tribal representatives, veterans’ groups, clinicians, researchers, and communities historically affected by drug enforcement (through advisory/consultation roles and social opportunity provisions).
- Insurers and federal contractors are not required to cover or to permit psilocybin activities beyond federal restrictions.
Procedural / timeline notes
- The enacted 2023 law establishes advisory bodies and directs study, rulemaking authority, and a pilot program; it contemplates a program development period (two years in some bill text versions) during which DOH adopts implementing rules before licensed manufacture/service provision begins.
- The HCA Task Force was required to provide a final report (document referenced a Dec. 1, 2023 deadline). Advisory board meeting schedule and member terms are specified in statute.
- Governor’s partial veto (5/9/2023) altered portions of the enacted bill; check the veto message and the final chapter text (Chapter 364, 2023 Laws) for the exact operative provisions after veto.
- Because the bill set up multi‑agency processes, phased implementation depends on DOH rulemaking, interagency work products, and any subsequent legislative or budget actions to fund implementation and licensing.
Notes / context
- The statute is mainly a framework-setting and planning law (advisory bodies, study, pilot research, and rulemaking authority). Full operational access to regulated psilocybin services requires subsequent DOH rules, licensing systems, and likely additional administrative setup and funding.
- For precise operative language, current administrative rules, and the governor’s veto details, consult: Chapter 364, Laws of 2023 (ESSB 5263 as enacted), the DOH rulemaking docket, and the governor’s veto message.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
